After successful completion of this regimen, the patient sustained pCR with a small focus of DCIS and no nodal metastases, suggesting the potential benefit of neoadjuvant chemoimmunotherapy in treating a subset of ER+ErbB2- patients with high-risk, basal-type breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.